[New dopaminergic agonists].
We present a brief review of the literature about dopaminergic agonists. We report the five known dopaminergic receptors, where they are located, the advantages and disadvantages of the employment in parkinsonian patients. The dopaminergic agonists were introduced to control the limitations of levodopa-increasing the therapeutic window. We analyse the pharmacocynetic efficacy and the side effects of cabergoline, ropinirole and pramipexole.
Serviço de Neurologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (UFRJ), Brasil.
J P
JP
de Mattos
V M
VM
Mattos
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007980:Levodopa
Novos agonistas dopaminérgicos.